Most Read Articles
Pank Jit Sin, 13 May 2020
A trial vaccine for the prevention of COVID-19 is underway with the first US participants being dosed in the Phase 1/2 clinical trial. Known as the BNT162 vaccine programme, the trials are a collaboration between Pfizer Inc. and BioNTech SE, and is part of a global development programme with Germany and the US taking the lead in having the first cohorts to be vaccinated. Germany started the study 1 week earlier. 
Jairia Dela Cruz, 18 Dec 2020
Rinsing with mouthwash that contains povidone-iodine (PI) or cetylpyridinium chloride (CPC) helps reduce SARS-CoV-2 levels in the saliva of COVID-19 patients, with the effect persisting for up to 6 hours, as shown in a study from Singapore.

COVID-19 pneumonia outcomes similar with favipiravir–inhaled interferon beta, HCQ

21 Dec 2020

The combination of favipiravir plus inhaled interferon beta-1b shows comparable outcomes with hydroxychloroquine (HCQ) in the treatment of patients with moderate-to-severe COVID-19 pneumonia, according to the results of an open-label trial.

A total 89 adult patients (mean age, 55 years; 58 percent male) received either a combination of favipiravir plus interferon beta-1b by inhalation aerosol (n=44) or HCQ alone (n=45). The most prominent symptoms recorded were fever (82 percent), shortness of breath (79 percent), and sore throat (39 percent). Many patients had chronic kidney disease (CKD; 75 percent), hypertension (54 percent), diabetes mellitus (45 percent), or heart disease (15 percent).

The majority of patients were managed with antibiotics (97 percent), steroids (67 percent), and convalescent plasma (58 percent). Clinical characteristics were similar in the treatment groups, but patients on favipiravir were more likely to have severe COVID-19 and end-stage CKD compared with those on HCQ (p=0.009).

Treatment outcomes did not differ between the combination and HCQ, including inflammatory biomarkers at hospital discharge (C-reactive protein, p=0.413; ferritin, p=0.968; lactate dehydrogenase, p=0.259; interleukin-6, p=0.410).

The two treatment groups also had similar overall length of hospital stay (7 vs 7 days; p=0.948), transfers to the ICU (18.2 percent vs 17.8 percent; p=0.960), discharges (65.9 percent vs 68.9 percent; p=0.764), and overall mortality (11.4 percent vs 13.3 percent; p=0.778).

More trials are needed to validate the present findings.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pank Jit Sin, 13 May 2020
A trial vaccine for the prevention of COVID-19 is underway with the first US participants being dosed in the Phase 1/2 clinical trial. Known as the BNT162 vaccine programme, the trials are a collaboration between Pfizer Inc. and BioNTech SE, and is part of a global development programme with Germany and the US taking the lead in having the first cohorts to be vaccinated. Germany started the study 1 week earlier. 
Jairia Dela Cruz, 18 Dec 2020
Rinsing with mouthwash that contains povidone-iodine (PI) or cetylpyridinium chloride (CPC) helps reduce SARS-CoV-2 levels in the saliva of COVID-19 patients, with the effect persisting for up to 6 hours, as shown in a study from Singapore.